Aptose Biosciences Inc. Daily Stock Analysis

Daily Stock Analysis, APTO, Aptose Biosciences Inc, priceseries

Aptose Biosciences Inc. Daily Stock Analysis
Stock Information
Open
1.10
Close
1.07
High
1.11
Low
1.06
Previous Close
1.12
Daily Price Gain
-0.05
YTD High
1.55
YTD High Date
Jan 3, 2022
YTD Low
1.06
YTD Low Date
Mar 7, 2022
YTD Price Change
-0.45
YTD Gain
-29.61%
52 Week High
7.20
52 Week High Date
Mar 24, 2021
52 Week Low
1.06
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-2.43
52 Week Gain
-69.43%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 10. 2017
1.19
Mar 14. 2017
1.28
2 Trading Days
7.56%
Link
LONG
May 1. 2017
0.90
May 11. 2017
1.09
8 Trading Days
21.48%
Link
LONG
Jun 9. 2017
1.22
Jun 14. 2017
1.30
3 Trading Days
6.97%
Link
LONG
Nov 8. 2017
1.61
Nov 16. 2017
1.78
6 Trading Days
10.48%
Link
LONG
Dec 8. 2017
1.95
Dec 12. 2017
2.06
2 Trading Days
5.64%
Link
LONG
Jan 10. 2018
2.29
Jan 26. 2018
3.01
11 Trading Days
31.33%
Link
LONG
Mar 2. 2018
2.80
Mar 23. 2018
3.50
15 Trading Days
24.89%
Link
LONG
Jun 1. 2018
3.59
Jun 14. 2018
3.90
9 Trading Days
8.69%
Link
LONG
Mar 13. 2019
1.81
Mar 27. 2019
2.10
10 Trading Days
16.28%
Link
LONG
Jun 24. 2019
2.23
Jul 12. 2019
2.66
13 Trading Days
19.15%
Link
LONG
Oct 31. 2019
2.08
Nov 15. 2019
2.38
11 Trading Days
14.62%
Link
LONG
Nov 18. 2019
2.42
Dec 2. 2019
2.55
9 Trading Days
5.28%
Link
LONG
Dec 9. 2019
3.54
Jan 8. 2020
5.14
20 Trading Days
45.19%
Link
LONG
Jan 28. 2020
6.04
Feb 24. 2020
7.95
18 Trading Days
31.65%
Link
LONG
Apr 6. 2020
6.06
Apr 27. 2020
7.15
14 Trading Days
18.01%
Link
LONG
Nov 11. 2020
5.23
Dec 3. 2020
6.36
15 Trading Days
21.70%
Link
LONG
Aug 23. 2021
2.69
Sep 10. 2021
2.84
13 Trading Days
5.46%
Link
LONG
Nov 1. 2021
2.20
Nov 18. 2021
2.52
13 Trading Days
14.72%
Link
Company Information
Stock Symbol
APTO
Exchange
NasdaqCM
Company URL
http://www.aptose.com
Company Phone
647-479-9828
CEO
William G. Rice
Headquarters
Ontario
Business Address
5955 AIRPORT ROAD, SUITE 228, ., MISSISSAUGA, CANADA L4V 1R9
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000882361
About

Aptose Biosciences, Inc. is a clinical-stage oncology company, which focuses on the discovery, research and development of anticancer therapies. Its product portfolio includes APTO-253, a small molecule that induce expression of the Kruppel-Like Factor 4 (KLF4) genes; and CG'806. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

Description

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, a small molecule that induces the transcription of the Kruppel-like factor 4 Gene in in vitro studies and in in vivo pharmacodynamic studies of human xenograft tumors in mice. The company's APTO-253 clinical program has completed Phase-I clinical trials for the treatment of various solid tumors; and Phase-Ib clinical trials for relapsed/refractory hematologic malignancies. It also develops APTO-500 program that focuses on discovering and developing small molecule inhibitors of maternal embryonic leucine zipper kinase; and is in a pre-clinical stage for oncology. It has a license agreement with Genentech Inc. to develop and sub-license a specified polypeptide; and collaboration agreement with Eli Lilly and Company to investigate a proprietary series of the company's compounds for veterinary medicine. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading